IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: CML stem cells have been shown to be resistant to the administration of the second generation inhibitors dasatinib and nilotinib.18,19 Concomitant administration of IFN-α may increase the proportion of CML patients achieving deep molecular responses that may lead to treatment discontinuation.